Comparative Pharmacology
Head-to-head clinical analysis: KELNOR 1 50 versus VOLNEA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KELNOR 1 50 versus VOLNEA.
KELNOR 1/50 vs VOLNEA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination hormonal contraceptive: ethinyl estradiol provides estrogenic activity, suppressing gonadotropin release; norethindrone acetate provides progestational activity, inhibiting ovulation and causing cervical mucus thickening.
Volnea is a combination of dienogest and ethinylestradiol. Dienogest is a progestin with antiandrogenic activity, and ethinylestradiol is an estrogen. The contraceptive effect is achieved through suppression of gonadotropins (FSH and LH), inhibition of ovulation, and changes in cervical mucus and endometrium.
One tablet (norethindrone 1 mg/ethinyl estradiol 50 mcg) orally once daily, taken at the same time each day for 21 days, followed by 7 days of placebo.
One tablet (0.02 mg ethinylestradiol + 3 mg drospirenone) orally once daily for 21 consecutive days, followed by a 7-day hormone-free interval.
None Documented
None Documented
Ethinyl estradiol: biphasic, terminal half-life 13-27 hours (mean ~17 h); norethindrone: monoexponential, half-life 5-14 hours (mean ~8 h). Steady-state achieved after 3-5 days. Accumulation may occur in patients with hepatic impairment.
Terminal half-life: 12 hours (range 10-14 h). Supports twice-daily dosing in patients with normal renal function.
Renal: ~50% (as metabolites, primarily ethinyl estradiol glucuronide and sulfate conjugates; norethindrone metabolites). Fecal: ~35% (biliary excretion of conjugates followed by hydrolysis and elimination). Unchanged drug: <5%.
Renal: 70% unchanged; fecal: 30% (biliary elimination)
Category C
Category C
Oral Contraceptive
Oral Contraceptive